Raymond James Issues Pessimistic Forecast for Xilio Therapeutics (NASDAQ:XLO) Stock Price

Xilio Therapeutics (NASDAQ:XLO) had its price target reduced by analysts at Raymond James from $6.00 to $4.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Raymond James’ price objective points to a potential upside of 304.00% from the stock’s previous close.

Xilio Therapeutics Stock Performance

NASDAQ XLO opened at $0.99 on Friday. The company has a market cap of $43.51 million, a PE ratio of -0.47 and a beta of -0.24. The firm’s 50 day moving average price is $0.88 and its 200-day moving average price is $0.95. Xilio Therapeutics has a 52-week low of $0.49 and a 52-week high of $1.93.

Xilio Therapeutics (NASDAQ:XLO) last announced its earnings results on Thursday, August 8th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.01). The business had revenue of $2.36 million during the quarter, compared to analyst estimates of $30.00 million. On average, analysts forecast that Xilio Therapeutics will post -1.26 earnings per share for the current fiscal year.

Institutional Trading of Xilio Therapeutics

A hedge fund recently bought a new stake in Xilio Therapeutics stock. XTX Topco Ltd bought a new stake in shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 33,289 shares of the company’s stock, valued at approximately $32,000. XTX Topco Ltd owned about 0.08% of Xilio Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 54.29% of the company’s stock.

Xilio Therapeutics Company Profile

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.